Biome Australia Quarterly Activities & Appendix 4C June 2024
Biome has released their Quarterly for June 24. It is once again an outstanding report and continues to underline why Canary Capital regard the company as a quality, high growth conviction stock.
The highlights are:
- Record cash receipts of $3.23m in Q4 FY24, up 118% vs PCP
- Record quarterly sales revenue of $3.8m, up 88% vs PCP
- Accounts receivable increase from $2.44m to $2.99m over the quarter
- Maintenance of gross margin above 60% for Q4 FY24
- As at June 30, the company has a cash balance of $2.86m
- A third consecutive quarter of positive cash flow for Q4 FY24
- A second consecutive quarter of positive EBITDA for Q4 FY24
- Same-store pharmacy sales for Q4 up 78% vs PCP
Biome Australia’s Founder and Managing Director, Blair Norfolk has commented “I’m pleased to share this quarterly activity report for June 2024, Biome’s best quarter, to date. With FY25 now underway, Biome is excited to continue driving its highly successful growth strategy, led by business development of our existing network of pharmacies and health practitioners, new product development, and supporting our early-stage international markets”.
ASX Announncement